Medical Product Alert N° 2/2019
This Medical Product Alert relates to confirmed falsified versions of ICLUSIG 15mg and ICLUSIG 45mg circulating in the WHO Region of Europe and the WHO Region of the Americas. Genuine ICLUSIG, the active pharmaceutical ingredient of which is Ponatinib Hydrochloride, is used to treat different forms of leukaemia.
On 15 January 2019, WHO was informed by health authorities in Switzerland that a local wholesaler had purchased packs of ICLUSIG 15mg : upon verification, the market authorization holder confirmed these packs as falsified. Further investigation confirmed that there are two versions of falsified ICLUSIG being traded globally, including via internet sales, detailed in the below table: